Bristol-Myers Squibb on Thursday struck a $19.5 million settlement to resolve claims by 43 states, including Massachusetts, that it marketed an antipsychotic drug to elderly patients and children for unapproved conditions. Massachusetts Attorney General Maura Healey said in a statement that more than $400,000 of the funds would go to the state. BMS (BMY), which is headquartered in New York City and has a manufacturing facility in Devens, Mass., was accused of engaging in unfair and deceptive trade practices through its marketing of Abilify.

Bristol-Myers Squibb Co. will pay $19.5 million to settle allegations that it promoted the anti-psychotic drug Abilify for unapproved uses and misled doctors about its dangers, it was announced Thursday. ...